Earnings Ahead

BIIB - Biogen Inc

181.98 1.23 0.68

Biogen Inc

Biogen Inc

About

Profile

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies


Headquarters

Cambridge, Massachusetts, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

BIIB



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Biogen raises 2025 EPS guidance to $15.50-$16 as new launches drive 7% revenue growth
  • Earnings Snapshot: Biogen tops Q2 estimates, raises FY EPS outlook
  • Biogen reports Q2 results
  • Biogen rises as Alzheimer’s therapy drives Q2 beat
  • Biogen Q2 2025 Earnings Preview
  • Eisai/Biogen, Eli Lilly highlight long-term data backing Alzheimer’s drugs
  • KalVista, Biogen, Ionis get EU positive opinions for key drugs
  • Biogen to invest additional $2B in North Carolina’s Research Triangle Park
  • Biogen sees negative Q2 impact from IPR&D, milestone expenses
  • Biogen starts phase 3 trial of felzartamab for kidney disease
  • Biogen lauds benefits of higher dose Spinraza for spinal muscular atrophy
  • Biogen’s salanersen shows promise in SMA, heads toward registrational trials
  • Lilly to appeal as U.K. declines to endorse use of new Alzheimer’s drugs
  • Biogen and City Therapeutics partner to develop RNAi therapies
  • Eli Lilly’s Alzheimer’s drug cleared in Australia despite setback for Biogen
  • FDA greenlights first blood test to diagnose Alzheimer's disease
  • Insider trades: Microsoft, JPMorgan, Boeing among notable names this week
  • Biogen outlines growth strategy with LEQEMBI and SKYCLARYS advancements for 2025
  • Earnings Snapshot: Biogen FY profit outlook misses estimates even as Q1 beats
  • Biogen Non-GAAP EPS of $3.02, revenue of $2.43B

Earnings History

Date EPS / Forecast Revenue / Forecast
February 3, 2022 3.39 / 3.35 2.73B / 2.62B Beat!
October 20, 2021 4.77 / 4.09 2.78B / 2.67B Beat!
July 22, 2021 5.68 / 4.55 2.78B / 2.61B Beat!
April 22, 2021 5.34 / 4.98 2.69B / 2.65B Beat!
February 3, 2021 4.58 / 4.79 2.85B / 2.8B Beat!
October 21, 2020 8.84 / 8.09 3.38B / 3.33B Beat!
July 22, 2020 10.26 / 8.02 3.68B / 3.43B Beat!
April 22, 2020 9.14 / 7.72 3.53B / 3.42B Beat!
January 30, 2020 8.34 / 8.03 3.67B / 3.54B Beat!
October 22, 2019 9.17 / 8.3 3.6B / 3.54B Beat!
July 23, 2019 9.15 / 7.53 3.62B / 3.47B Beat!
April 24, 2019 6.98 / 6.97 3.49B / 3.4B Beat!
January 29, 2019 6.99 / 6.73 3.53B / 3.39B Beat!
October 23, 2018 7.4 / 6.78 3.44B / 3.33B Beat!
July 24, 2018 5.8 / 5.21 3.36B / 3.25B Beat!
April 24, 2018 6.05 / 5.93 3.13B / 3.15B
January 25, 2018 5.26 / 5.45 3.31B / 3,080M Beat!
October 24, 2017 6.31 / 5.73 3.08B / 3,044M Beat!
July 25, 2017 5.04 / 5.62 3.08B / 2.81B Beat!
April 25, 2017 5.2 / 4.6 2.81B / - Beat!
January 26, 2017 5.04 / 5.01 2.87B / 2.94B
Date Price Open High Low Vol Change
Dec 4 181.98 181.86
182.69
179.27
1.2M 0.68%
Dec 3 180.75 180.17
182.94
178.05
1.8M 0.32%
Dec 2 180.18 177.32
180.54
174.53
1.9M 1.35%
Dec 1 177.78 180.15
181.78
175.88
1.9M -2.37%
Nov 28 182.09 182.07
182.74
180.68
566K 0.08%
 
Nov 26 181.94 181.96
183.93
180.76
1.5M -0.01%
Nov 25 181.96 177.07
182.97
176.09
2.3M 2.91%
Nov 24 176.82 177.65
185.17
175.57
4.2M 0.87%
Nov 21 175.3 168.54
176.02
167.42
2.3M 4.23%
Nov 20 168.18 168.15
170.91
165.75
1.9M 0.15%
Nov 19 167.93 168.83
168.9
165.79
1.8M -0.53%
Nov 18 168.83 164.4
170.78
163
2.3M 2.52%
Nov 17 164.68 167
167.97
163.5
2.2M -1.71%
Nov 14 167.55 164.72
169
163
2.6M 1.71%
Nov 13 164.73 161.57
167.87
161.2
3.0M 2.01%
Nov 12 161.48 160
162.56
158.05
1.7M 1.20%
Nov 11 159.56 156.76
159.95
154.2
1.5M 2.11%
Nov 10 156.26 155.41
156.55
153.77
1.3M 0.48%
Nov 7 155.51 156.7
156.7
151.83
1.6M -0.78%
Nov 6 156.74 155.76
157.8
153.76
1.8M 2.16%
Nov 5 153.43 149.66
153.68
148.51
1.8M 2.75%
Nov 4 149.33 150.89
152.9
149.05
2.0M -1.39%
Nov 3 151.44 153.6
155.33
149.63
2.2M -1.83%
Oct 31 154.27 147.99
155.18
146.52
2.2M 3.11%
Oct 30 149.61 140.1
154.44
138
2.7M 1.18%
Oct 29 147.86 148.82
149.91
147.54
2.5M -0.85%
Oct 28 149.13 150.01
150.3
148.37
1.7M -0.86%
Oct 27 150.43 150.07
150.92
148.1
1.2M 0.36%
Oct 24 149.89 151.09
151.92
148.98
1.3M -0.13%
Oct 23 150.08 148.99
150.29
147.57
1.2M 1.60%
Oct 22 147.72 147.37
149.12
146.25
1.4M 1.03%
Oct 21 146.22 146.09
147.89
144.29
895K -0.28%
Oct 20 146.63 143.31
147.47
142.41
1.3M 2.54%
Oct 17 143 142.1
144.32
141.67
1.0M 0.52%
Oct 16 142.26 144.05
147.48
141.7
1.5M -0.97%
Oct 15 143.66 144.74
145.18
142.29
1.3M -1.14%
Oct 14 145.31 144.09
146.88
142.2
1.3M 0.43%
Oct 13 144.69 146.47
147.55
144.65
1.1M -1.28%
Oct 10 146.57 150
150.2
144.74
1.7M -2.03%
Oct 9 149.61 151.37
152.15
148.17
1.6M -0.9%
Oct 8 150.97 152.36
152.36
149.64
1.3M -0.81%
Oct 7 152.21 154.52
154.57
151.97
1.4M -1.19%
Oct 6 154.05 159.6
159.7
153.1
1.8M -3.65%
Oct 3 159.88 156.46
160.2
155.97
2.9M 2.98%
Oct 2 155.25 154
157.85
152.22
2.9M 0.67%
Oct 1 154.22 140.82
154.44
140.7
4.1M 10.09%
Sep 30 140.08 138.46
141.04
136.93
1.4M 1.13%
Sep 29 138.52 137.49
138.8
135.39
1.3M 0.84%
Sep 26 137.37 136.79
138
135.81
1.7M 1.25%
Sep 25 135.67 138.4
140.67
135.4
1.3M -1.45%
Sep 24 137.67 138.52
139.28
136.2
1.3M -1.18%
Sep 23 139.31 140.27
141.38
138.73
1.1M -0.96%
Sep 22 140.66 142.12
142.64
140.02
1.4M -1.29%
Sep 19 142.5 143.96
144.43
141.49
3.7M -0.91%
Sep 18 143.81 146.3
146.45
143.37
1.5M -0.73%
Sep 17 144.87 143.48
146.68
143.39
1.5M 0.83%
Sep 16 143.68 143.51
147.23
143.02
1.9M 0.25%
Sep 15 143.32 144.82
145.99
141.12
1.4M -1.06%
Sep 12 144.86 148.08
150.28
144.84
1.8M -2.67%
Sep 11 148.84 143.47
149.07
142.86
1.7M 0%